Akari Therapeutics Statistics
Share Statistics
Akari Therapeutics has 25.54M shares outstanding. The number of shares has increased by 140.21% in one year.
| Shares Outstanding | 25.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 53.27% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 12.10M |
| Failed to Deliver (FTD) Shares | 1.12K |
| FTD / Avg. Volume | 2.92% |
Short Selling Information
The latest short interest is 21.29K, so 0.15% of the outstanding shares have been sold short.
| Short Interest | 21.29K |
| Short % of Shares Out | 0.15% |
| Short % of Float | 0.15% |
| Short Ratio (days to cover) | 1.92 |
Valuation Ratios
The PE ratio is -1.53 and the forward PE ratio is -0.68.
| PE Ratio | -1.53 |
| Forward PE | -0.68 |
| PS Ratio | 0 |
| Forward PS | 7.2 |
| PB Ratio | -66.68 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Akari Therapeutics has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 0.
| Current Ratio | 0.95 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 43.7% and return on capital (ROIC) is 7338.86%.
| Return on Equity (ROE) | 43.7% |
| Return on Assets (ROA) | -2.3% |
| Return on Capital (ROIC) | 7338.86% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.67M |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -64.29% in the last 52 weeks. The beta is 0.95, so Akari Therapeutics's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -64.29% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.45 |
| Relative Strength Index (RSI) | 27.99 |
| Average Volume (20 Days) | 38.55K |
Income Statement
In the last 12 months, Akari Therapeutics had revenue of $0 and earned -$10.01M in profits. Earnings per share was $-2.04.
| Revenue | 0 |
| Gross Profit | -4.00K |
| Operating Income | -16.81M |
| Net Income | -10.01M |
| EBITDA | -16.80M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.04 |
Balance Sheet
The company has $3.85M in cash and $0 in debt, giving a net cash position of $3.85M.
| Cash & Cash Equivalents | 3.85M |
| Total Debt | 0 |
| Net Cash | 3.85M |
| Retained Earnings | -227.46M |
| Total Assets | 2.73M |
| Working Capital | -6.69M |
Cash Flow
In the last 12 months, operating cash flow was -$16.43M and capital expenditures $0, giving a free cash flow of -$16.43M.
| Operating Cash Flow | -16.43M |
| Capital Expenditures | 0 |
| Free Cash Flow | -16.43M |
| FCF Per Share | -3.36 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
AKTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -204% |
| FCF Yield | -64.34% |
Analyst Forecast
Currently there are no analyst rating for AKTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 17, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Aug 17, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -151.2 |
| Piotroski F-Score | 1 |